drugset / Trial / NCT01202890
Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study will test the feasibility of combining 3 drugs, Revlimid with Doxil and Bevacizumab,and gather preliminary data on the potential activity of the combination in patients with platinum resistant/refractory ovarian cancer.
Timeline
- Start
- 2010-09
- Primary completion
- 2011-05
- Completion
- 2012-05
Outcome
Outcome not reported
Stopped (Enrollment): “Terminated due to inadequate rate of accrual.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | — |
| Subject | Doxorubicin | Other / unclassified | 30 mg/m2 | — |
| Subject | Lenalidomide | Other / unclassified | 25 mg | Oral |